Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 1;23(4):413–423. doi: 10.1038/s41556-021-00637-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 7 — a, Schematic illustration of the strategy to generate a conditional Ogdh knockout allele, in which exons 3 and 4 are flanked by loxP sites (red triangles). The Ogdh genomic locus, the targeting vector, the targeted allele and the SDA- and cre-recombined loci are shown. SDA-Neo-SDA, neomycin resistance cassette flanked by SDA sites. b, Immunofluorescence staining for ERG (cyan) and PECAM1 (PECAM, red) of control (Ctrl, Ogdh^fl/fl) and endothelial-restricted Ogdh knockout (Ogdh^EC-KO, Tie2-cre;Ogdh^fl/fl) yolk sacs at E11.5, showing reduced vascular density after Ogdh loss. c, Quantifications of vascular parameters in E11.5 Ctrl and Ogdh^EC-KO yolk sacs, as indicated, (EC area: n=7, 4 samples for Ctrl and Ogdh^EC-KO; Number of ECs: n=7, 4 samples for Ctrl and Ogdh^EC-KO). d, PCR analysis of genomic DNA from control (Ogdh^+/+, lane 2; Ogdh^fl/+, lane 3; Ogdh^fl/fl, lane5) and conditional Ogdh mutant mice (Cdh5-creERT2; Ogdh^fl/+, lane4; Cdh5-creERT2;Ogdh^fl/fl, lane 6). Lane 1, DNA marker (M). e, Immunoblot analysis of OGDH protein levels in ECs isolated from the liver of 4-OHT-injected Ctrl (Ogdh^fl/fl) and Ogdh^iEC-KO (Cdh5-creERT2;Ogdh^fl/fl) mouse mutants. GAPDH served as loading control. f, Quantifications of vascular parameters in P6 Ctrl and Ogdh^iEC-KO mouse mutants, as indicated (Filopodia per vessel segment: n=10, 8 samples for Ctrl and Ogdh^iEC-KO; Branching frequency: n=10, 8 samples for Ctrl and Ogdh^iEC-KO; Regression index: n=5, 3 samples for Ctrl and Ogdh^iEC-KO). g, Immunostaining showing ICAM2- (ICAM, green), PECAM- (blue), and collagen IV- (COL, red) labelling of P6 retinas from 4-OHT-injected Ctrl and Ogdh^iEC-KO mice. Western blot data in e were from the respective experiment, processed in parallel, and are representative of at least three independent experiments. c and f, Data represent mean ± s.e.m.; a two-tailed unpaired t-test was used; ** P< 0.01; ***P<0.001; ****P<0.0001; NS, not significant. The numerical data, unprocessed western blots and P values are provided as source data.

Source data